Invivogen
Menu

Human TIGIT-expressing Raji Cells

Raji-hTIGIT Cells Unit size Cat. code Docs Qty Price
Human lymphoblast cells - ADCC TIGIT Target Cells
3-7 x 10e6 cells
raji-htigit
+-
$1,141.00

Human TIGIT-expressing B cells

Raji-hTIGIT cells were developed from the Raji cell line, a human B lymphocyte-derived cell line. Raji cells have been successfully used as target cells in human effector studies such as antibody-dependent cellular cytotoxicity (ADCC), either with peripheral blood mononuclear cells, natural killer (NK) cells, or T cell-derived Jurkat reporter cells.

TIGIT (T cell immunoglobulin and ITIM domain) is an inhibitory checkpoint that has been implicated in tumor immunosurveillance. TIGIT is specifically expressed on immune cells including natural killer (NK) cells and activated T cells [1]. TIGIT binds to CD155 (PVR) and CD112 (PVRL2, nectin-2), which are expressed on antigen‑presenting cells (APCs) and a variety of non-hematopoietic cells (e.g. tumor cells) [1,2]. Upon binding to its ligand, TIGIT inhibits a number of signaling pathways, leading to a strong reduction of NK cytotoxicity, and blockade of T cell activation, proliferation, and effector functions [2,3]. The blockade of TIGIT is highly favorable in cancer immunotherapy due to its low expression in peripheral lymphoid organs, its established synergy with other co-inhibitory immune checkpoints, and its ligands being widely expressed on tumor cells [1,2].

Features of Raji-hTIGIT cells:

Surface expressed markers and ICs in Raji-hTIGIT cells
Surface expressed markers and ICs in Raji-hTIGIT cells

  • Stable overexpression of the human TIGIT gene 
  • Characterized by a number of cell-surface expressed markers including the B cell receptor (BCR), CD19, and CD20
  • Constitutive expression of various immune checkpoints (ICs) such as CD27, CD70, CD80, PD-L1, and 4-1BBL
  • The stability for 20 passages following thawing has been verified

Applications for Raji-hTIGIT cells:

  • Target cell line for ADCC assays using InvivoGen's Jurkat-Lucia™ NFAT-CD16 cells
  • Target cell line for cell toxicity assays using NK or CAR-T cells
  • For use in the development of other functional assays

Validation of Raji-hTIGIT cells:

 

References:

1. Solomon, B. L. et al, 2018. TIGIT: a novel immunotherapy target moving from bench to bedside. Cancer Immunol Immunother 67, 1659-1667.
2. Anderson, A.C. et al. 2016. Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation. Immunity 44, 989-1004.
3. Joller, N. et al. 2011. Cutting edge: TIGIT has T cell-intrinsic inhibitory functions. J Immunol 186, 1338-1342.

Figures

TIGIT is expressed by Raji-hTIGIT cells
TIGIT is expressed by Raji-hTIGIT cells

Validation of the expression of human TIGIT by Raji-hTIGIT cells: Raji-Null (A) and Raji‑hTIGIT (B) cells were incubated with a PE-conjugated Anti-hTIGIT mAb for 30 minutes. The binding affinity was then measured using flow cytometry

Comparison of ADCC potency for native and engineered anti-human TIGIT antibody isotypes
Comparison of ADCC potency for native and engineered anti-human TIGIT antibody isotypes

Comparison of ADCC potency for native and engineered anti-human TIGIT antibody isotypes: Raji-hTIGIT cells were incubated with gradient concentrations of Anti-hTIGIT or Anti-β-galactosidase (β-gal) mAbs for 1 hour. Jurkat-Lucia™ NFAT-CD16 effector cells were then co-incubated with target cells for 6 hours. NFAT activation, reflecting the induced ADCC response, was assessed by determining Lucia luciferase activity in the supernatant using QUANTI-Luc™. Percentages of the maximal response normalized to the IgG1 isotype are shown.

Back to the top

Specifications

Antibiotic resistance: Blasticidin

Growth medium: IMDM, 2 mM L-glutamine, 25 mM HEPES, 10% heat-inactivated fetal bovine serum (FBS; 30 min at 56 °C), 10 μg/ml Blasticidin, Pen-Strep (100 U/ml-100 µg/ml)

Test medium: IMDM, 2 mM L-glutamine, 25 mM HEPES, 10% heat-inactivated FBS, Pen-Strep (100 U/ml-100 µg/ml)

Quality control:

  • Human TIGIT expression has been verified by flow-cytometry.
  • Induction of antibody-dependent cellular cytotoxicity (ADCC) has been validated using InvivoGen’s anti-hTIGIT-hIgG1 antibody and Jurkat-NFAT Lucia™ CD16 reporter cell line.
  • The stability for 20 passages following thawing has been verified.
  • Raji-hTIGIT cells are guaranteed mycoplasma-free.

These products are covered by a Limited Use License (See Terms and Conditions).

Back to the top

Contents

  • 3-7 x 106 Raji-hTIGIT cells in a cryovial or shipping flask.
  • 1 ml of Blasticidin (10 mg/ml). Store at 4 °C or at -20 °C.
  • 1 ml of Normocin™ (50 mg/ml). Normocin™ is a formulation of three antibiotics active against mycoplasmas, bacteria, and fungi. Store at -20 °C.

IMPORTANT: If cells are shipped frozen (i.e. in a cryovial) and are not frozen upon arrival, contact InvivoGen immediately.

Shipped on dry ice Shipped on dry ice (Europe, USA & Canada)

Back to the top

FAQ

Any questions about our cell lines ? Visit our frequently asked questions page

Back to the top
Customer Service
& Technical Support
Shopping cart is empty